CASIRIVIMAB
Tracking # 20-849445
$99999.00
There are no ratings for this course
Learn more Educator STATPEARLS PUBLISHING, LLC
CE Broker Reporting Reported automatically
Method Computer-Based Training
Course overview
CASIRIVIMAB IS ONE OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) NEUTRALIZING ANTIBODIES PROPOSED FOR USE IN THE CLINICAL MANAGEMENT OF CORONAVIRUS DISEASE 2019 (COVID-19). WHEN USED IN COMBINATION WITH IMDEVIMAB, IT REDUCES VIRAL LOAD AND IMPROVES CLINICAL OUTCOMES. THIS ACTIVITY REVIEWS THE INDICATIONS, CONTRAINDICATIONS, ACTIVITY, ADVERSE EVENTS, AND OTHER KEY ELEMENTS OF CASIRIVIMAB THERAPY IN THE CLINICAL SETTING AND ALSO HIGHLIGHTS THE ESSENTIAL POINTS NEEDED BY MEMBERS OF AN INTERPROFESSIONAL TEAM MANAGING COVID-19 PATIENTS.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Specialty Medical Practitioner
1h
General Medicine
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
1h
Category I CME
Mississippi State Board of Medical Licensure
Medical Doctor
1h
AMA Category I
Physician Assistant
1h
AMA Category I
State Medical Board of Ohio
Doctor of Medicine
1h
AMA Category I